In the absence of a submission from the holder of the marketing authorisation, chenodeoxycholic acid (Chenodeoxycholic acid Leadiant®) cannot be endorsed for use within NHS Wales for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis) in infants, children and adolescents aged 1 month to 18 years and adults.